NCT04643639View on ClinicalTrials.gov

Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

October 19, 2022

Study Completion Date

October 19, 2022

Conditions
SepsisImmune DeficiencyHemoperfusionBlood Purification
Interventions
DEVICE

CytoSorb hemoperfusion

Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.

Trial Locations (1)

6500HB

Radboud University Medical Center, Nijmegen

All Listed Sponsors
collaborator

CytoSorbents Europe GmbH

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT04643639 - Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis | Biotech Hunter | Biotech Hunter